

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>OrbiMed Israel BioFund GP Limited Partnership</u>  (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.  (Street) HERZLIYA L3 46686  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BiomX Inc. [ PHGE ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/27/2023		P		348,000 <sup>(1)</sup>	A	\$0.245	3,161,489	I	See Footnotes <sup>(2)(3)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrants (Right to Buy)	\$0.244	02/27/2023		P		1,789,959		02/27/2023	02/27/2033	Common Stock	1,789,959	(1)	1,789,959	I	See Footnotes <sup>(2)(3)</sup>

1. Name and Address of Reporting Person * <u>OrbiMed Israel BioFund GP Limited Partnership</u>  (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.  (Street) HERZLIYA L3 46686  (City) (State) (Zip)
1. Name and Address of Reporting Person * <u>OrbiMed Israel GP Ltd.</u>  (Last) (First) (Middle) 5 HAHOSHLIM STREET, BUILDING B, 1ST FL.  (Street) HERZLIYA L3 46686  (City) (State) (Zip)

1. Name and Address of Reporting Person *		
<u>GORDON CARL L</u>		
(Last)	(First)	(Middle)
C/O ORBIMED ISRAEL GP LTD.		
5 HAHOSHLIM STREET, BUILDING B, 1ST FL.		
(Street)		
HERZLIYA PITUACH	L3	46686
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
<u>Chimovits Erez</u>		
(Last)	(First)	(Middle)
C/O ORBIMED ISRAEL GP LTD.		
5 HAHOSHLIM STREET, BUILDING B, 1ST FL.		
(Street)		
HERZLIYA PITUACH	L3	46686
(City)	(State)	(Zip)

**Explanation of Responses:**

1. These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants.
2. These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
3. Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

<u>OrbiMed Israel GP Ltd., By: /s/ Douglas Coon, Chief Compliance Officer</u>	<u>03/17/2023</u>
<u>OrbiMed Israel BioFund GP Limited Partnership, By: /s/ Douglas Coon, Chief Compliance Officer</u>	<u>03/17/2023</u>
<u>/s/ Carl L. Gordon</u>	<u>03/17/2023</u>
<u>/s/ Erez Chimovits</u>	<u>03/17/2023</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**